Boundless Bio, Inc.

Boundless Bio, Inc. has raised $100.0M in total funding. The most recent round was Series C.

Boundless Bio, Inc. is headquartered in San Diego, CA.

We at Boundless Bio are pioneers in understanding and treating the most intractable cancers. We have charted a new spatial map of the cancer genome within cancer cells and are harnessing our scientific founders’ discoveries about “extrachromosomal DNA,” or ecDNA, to drive a revolution in cancer therapeutics.

Over 25% of cancers involve oncogene amplifications, affecting more than 5 million newly diagnosed patients a year, yet current targeted therapies and immunotherapies are largely ineffective for them, leading to poor prognosis and survival.

Boundless Bio is a clinical-stage precision oncology company developing ecDNA-directed therapies (ecDTx) that target extrachromosomal DNA (ecDNA), the mechanism cancer cells use to drive these amplifications.

States it is the first company dedicated to treating oncogene-amplified cancers and the leader in the ecDNA field, exploiting a vulnerability found in cancer cells but rarely in healthy cells.

Boundless Bio was co-founded by biotech entrepreneur Jonathan Lim and has raised over $250M from investors including ARCH Venture Partners, RA Capital Management, and Bayer.